{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:05Z","timestamp":1790655065085,"version":"4.1.0"},"reference-count":125,"publisher":"Bioscientifica","issue":"3","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:p>Aldosterone is synthesized by the CYP11B2 enzyme, primarily in the zona glomerulosa of the adrenal gland. It exerts its classical effects on sodium and water balance in the renal distal nephron through binding to the mineralocorticoid receptor (MR). Excess aldosterone production or overactivation of the MR outside the distal nephron leads to cardiac, renal, and vascular injury by increasing oxidative stress and activating the inflammatory and fibrotic pathways. MR antagonists (MRAs) have proved effective at decreasing organ damage and the deleterious effects of excess aldosterone\/MR activation. However, MRAs do not fully block the non-genomic effects of aldosterone, which may contribute to residual risks. CYP11B2 inhibition has emerged as an additional therapeutic approach to decreasing the deleterious genomic and non-genomic effects of aldosterone. The development of specific aldosterone synthase inhibitors (ASi) has proved challenging due to the considerable similarity between aldosterone synthase and 11\u03b2-hydroxylase, an enzyme encoded by the CYP11B1 gene that catalyzes cortisol synthesis. In this review, we summarize the latest developments on preclinical evidence and clinical trials for ASi and explore the potential clinical advantages of ASi.<\/jats:p>","DOI":"10.1530\/jme-25-0047","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T16:54:41Z","timestamp":1757091281000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-6","source":"Crossref","is-referenced-by-count":4,"title":["Aldosterone synthase inhibition: a novel bullet to fight cardiovascular\u2013kidney\u2013metabolic syndrome"],"prefix":"10.1530","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0711-5092","authenticated-orcid":true,"given":"Jonatan","family":"Barrera-Chimal","sequence":"first","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont, Centre affili\u00e9 \u00e0 l\u2019Universit\u00e9 de Montr\u00e9al 1 , , ,","place":["Montr\u00e9al, Qu\u00e9bec, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Vaidya","sequence":"additional","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women\u2019s Hospital and Harvard Medical School 2 , , ,","place":["Boston, Massachusetts, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Jaisser","sequence":"additional","affiliation":[{"name":"INSERM, UMRS 1166, H\u00f4pital La Piti\u00e9 Salpetriere, Sorbonne Universit\u00e9 3 , ,","place":["Paris, France"]},{"name":"Universit\u00e9 de Lorraine, INSERM Centre d'Investigations Cliniques-Plurith\u00e9matique 1433, UMR 1116, CHRU de Nancy, French-Clinical Research Infrastructure Network (F-CRIN) INI-CRCT 4 , ,","place":["Nancy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"2026070811345950200_bib1","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/JME-15-0318","article-title":"Mineralocorticoid regulation of cell function: the role of rapid signalling and gene transcription pathways","volume":"58","author":"Ong","year":"2017","journal-title":"J Mol Endocrinol"},{"key":"2026070811345950200_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070811345950200_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fphar.2017.00313","article-title":"Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front Pharmacol"},{"key":"2026070811345950200_bib4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","article-title":"Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases","volume":"84","author":"Barrera-Chimal","year":"2022","journal-title":"Annu Rev Physiol"},{"key":"2026070811345950200_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.kisu.2021.11.004","article-title":"Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease","volume":"12","author":"Nakamura","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"2026070811345950200_bib6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"2026070811345950200_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.vh.2018.12.001","article-title":"Non-genomic effects of aldosterone","volume":"109","author":"Mihailidou","year":"2019","journal-title":"Vitam Horm"},{"key":"2026070811345950200_bib8","doi-asserted-by":"crossref","first-page":"T107","DOI":"10.1530\/JOE-16-0659","article-title":"30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Nongenomic effects via the mineralocorticoid receptor","volume":"234","author":"Ruhs","year":"2017","journal-title":"J Endocrinol"},{"key":"2026070811345950200_bib9","doi-asserted-by":"crossref","first-page":"T17","DOI":"10.1530\/JOE-17-0119","article-title":"30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor activation and specificity-conferring mechanisms: a brief history","volume":"234","author":"Funder","year":"2017","journal-title":"J Endocrinol"},{"key":"2026070811345950200_bib10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-pharmtox-010716-104651","article-title":"GPER (GPR30): a nongenomic receptor (GPCR) for steroid hormones with implications for cardiovascular disease and cancer","volume":"57","author":"Feldman","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026070811345950200_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease \u2013 mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2026070811345950200_bib12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the fidelity pooled analysis","volume":"43","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070811345950200_bib13","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","article-title":"Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases","volume":"110","author":"Azizi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070811345950200_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10741-005-2343-3","article-title":"Aldosterone biosynthesis, regulation, and classical mechanism of action","volume":"10","author":"Williams","year":"2005","journal-title":"Heart Fail Rev"},{"key":"2026070811345950200_bib15","doi-asserted-by":"crossref","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","article-title":"Aldosterone and aldosterone synthase inhibitors in cardiorenal disease","volume":"326","author":"Verma","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026070811345950200_bib16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijcard.2018.10.010","article-title":"Evidence of aldosterone synthesis in human myocardium in acute myocarditis","volume":"275","author":"Cardona","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026070811345950200_bib17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/01.HYP.0000175814.18550.c0","article-title":"Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor","volume":"46","author":"Xue","year":"2005","journal-title":"Hypertension"},{"key":"2026070811345950200_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.116.236463","article-title":"Selectivity of BI 689648, a novel, highly selective aldosterone synthase inhibitor: comparison with FAD286 and LCI699 in Nonhuman Primates","volume":"359","author":"Weldon","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"2026070811345950200_bib19","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026070811345950200_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070811345950200_bib21","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1056\/NEJMimc2401927","article-title":"Targeting a hormonal cause of hypertension","volume":"392","author":"Vaidya","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070811345950200_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070811345950200_bib23","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026070811345950200_bib24","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41581-023-00753-6","article-title":"Primary aldosteronism: molecular medicine meets public health","volume":"19","author":"Azizan","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"2026070811345950200_bib25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.molmed.2020.05.005","article-title":"Genetic and genomic mechanisms of primary aldosteronism","volume":"26","author":"Fernandes-Rosa","year":"2020","journal-title":"Trends Mol Med"},{"key":"2026070811345950200_bib26","doi-asserted-by":"crossref","first-page":"E4591","DOI":"10.1073\/pnas.1505529112","article-title":"Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands","volume":"112","author":"Nishimoto","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070811345950200_bib27","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/HYPERTENSIONAHA.118.11086","article-title":"Cellular and genetic causes of idiopathic hyperaldosteronism","volume":"72","author":"Omata","year":"2018","journal-title":"Hypertension"},{"key":"2026070811345950200_bib28","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1210\/js.2017-00134","article-title":"Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals","volume":"1","author":"Omata","year":"2017","journal-title":"J Endocr Soc"},{"key":"2026070811345950200_bib29","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1055\/s-0043-122394","article-title":"Aldosterone-producing cell clusters in normal and pathological states","volume":"49","author":"Omata","year":"2017","journal-title":"Horm Metab Res"},{"key":"2026070811345950200_bib30","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/ajh\/hpac079","article-title":"Primary aldosteronism: state-of-the-art review","volume":"35","author":"Vaidya","year":"2022","journal-title":"Am J Hypertens"},{"key":"2026070811345950200_bib31","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"key":"2026070811345950200_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.124.24153","article-title":"Characterizing the origins of primary aldosteronism","volume":"82","author":"Brown","year":"2025","journal-title":"Hypertension"},{"key":"2026070811345950200_bib33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026070811345950200_bib34","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"key":"2026070811345950200_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"2026070811345950200_bib36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/L18-0027","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"168","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026070811345950200_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2023","journal-title":"Circulation"},{"key":"2026070811345950200_bib38","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/CIRCULATIONAHA.124.070039","article-title":"Relationship between renin, aldosterone, aldosterone-to-renin ratio and arterial stiffness and left ventricular mass index in young adults","volume":"150","author":"Ananda","year":"2024","journal-title":"Circulation"},{"key":"2026070811345950200_bib39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.120.15006","article-title":"Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis","volume":"76","author":"Inoue","year":"2020","journal-title":"Hypertension"},{"key":"2026070811345950200_bib40","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1161\/CIRCULATIONAHA.120.050896","article-title":"Association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: the Jackson heart study","volume":"143","author":"Joseph","year":"2021","journal-title":"Circulation"},{"key":"2026070811345950200_bib41","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"2026070811345950200_bib42","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070811345950200_bib43","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2026070811345950200_bib44","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jchf.2020.11.010","article-title":"Proteomic and mechanistic analysis of spironolactone in patients at risk for HF","volume":"9","author":"Ferreira","year":"2021","journal-title":"JACC Heart Failure"},{"key":"2026070811345950200_bib45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41371-023-00891-1","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis","volume":"38","author":"Shah","year":"2024","journal-title":"J Hum Hypertens"},{"key":"2026070811345950200_bib46","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/HYPERTENSIONAHA.124.23385","article-title":"Update on low-renin hypertension: current understanding and future direction","volume":"81","author":"Shah","year":"2024","journal-title":"Hypertension"},{"key":"2026070811345950200_bib47","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1161\/HYPERTENSIONAHA.124.22884","article-title":"Comparing ARR versus suppressed PRA as screening tests for primary aldosteronism","volume":"81","author":"Marcelli","year":"2024","journal-title":"Hypertension"},{"key":"2026070811345950200_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1210\/endrev\/bnad024","article-title":"Biomarkers to guide medical therapy in primary aldosteronism","volume":"45","author":"Hundemer","year":"2023","journal-title":"Endocr Rev"},{"key":"2026070811345950200_bib49","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"key":"2026070811345950200_bib50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-8587(24)00308-5","article-title":"Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort","volume":"13","author":"Yang","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070811345950200_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.02.025","article-title":"Interaction between aldosterone and mineralocorticoid receptor antagonist: findings from the EPHESUS trial","volume":"13","author":"Kobayashi","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026070811345950200_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102519","article-title":"Escaping injury from elevated aldosterone: more data in support of MR antagonism","volume":"13","author":"Vardeny","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026070811345950200_bib53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ejendo\/lvaf007","article-title":"Mild autonomous cortisol secretion in patients with aldosterone-producing adenoma and risk for cardiac remodeling and diastolic dysfunction","volume":"192","author":"Tsai","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026070811345950200_bib54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070811345950200_bib55","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"2026070811345950200_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102576","article-title":"Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial","volume":"71","author":"Mulatero","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026070811345950200_bib57","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070811345950200_bib58","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"key":"2026070811345950200_bib59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"2026070811345950200_bib60","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1291\/hypres.31.363","article-title":"Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis","volume":"31","author":"Hayashi","year":"2008","journal-title":"Hypertens Res"},{"key":"2026070811345950200_bib61","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1210\/en.2003-1137","article-title":"Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C","volume":"145","author":"Mihailidou","year":"2004","journal-title":"Endocrinology"},{"key":"2026070811345950200_bib62","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1161\/HYPERTENSIONAHA.111.176024","article-title":"Aldosterone stimulates the cardiac Na(+)\/H(+) exchanger via transactivation of the epidermal growth factor receptor","volume":"58","author":"De Giusti","year":"2011","journal-title":"Hypertension"},{"key":"2026070811345950200_bib63","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.bbadis.2010.03.006","article-title":"Menage a trois: aldosterone, sodium and nitric oxide in vascular endothelium","volume":"1802","author":"Fels","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"2026070811345950200_bib64","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/01.HYP.0000226054.53527.bb","article-title":"Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity","volume":"48","author":"Nagata","year":"2006","journal-title":"Hypertension"},{"key":"2026070811345950200_bib65","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1291\/hypres.31.1811","article-title":"Aldosterone enhances ligand-stimulated nitric oxide production in endothelial cells","volume":"31","author":"Mutoh","year":"2008","journal-title":"Hypertens Res"},{"key":"2026070811345950200_bib66","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1161\/01.CIR.0000093188.53554.44","article-title":"Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation","volume":"108","author":"Liu","year":"2003","journal-title":"Circulation"},{"key":"2026070811345950200_bib67","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1210\/en.2004-1130","article-title":"Eplerenone blocks nongenomic effects of aldosterone on the Na+\/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels","volume":"146","author":"Michea","year":"2005","journal-title":"Endocrinology"},{"key":"2026070811345950200_bib68","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1210\/me.2006-0559","article-title":"Direct binding and activation of protein kinase C isoforms by aldosterone and 17\u03b2-estradiol","volume":"21","author":"Alzamora","year":"2007","journal-title":"Mol Endocrinol"},{"key":"2026070811345950200_bib69","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/01.CIR.99.11.1485","article-title":"Aldosterone, not estradiol, is the physiological agonist for rapid increases in cAMP in vascular smooth muscle cells","volume":"99","author":"Christ","year":"1999","journal-title":"Circulation"},{"key":"2026070811345950200_bib70","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s12020-012-9675-2","article-title":"Aldosterone-induced osteopontin expression in vascular smooth muscle cells involves MR, ERK, and p38 MAPK","volume":"42","author":"Fu","year":"2012","journal-title":"Endocrine"},{"key":"2026070811345950200_bib71","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.RES.0000180753.63183.95","article-title":"Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells","volume":"97","author":"Min","year":"2005","journal-title":"Circ Res"},{"key":"2026070811345950200_bib72","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000322965","article-title":"Nongenomic effects of aldosterone on renal protein expressions of pEGFR and pERK1\/2 in rat kidney","volume":"33","author":"Sinphitukkul","year":"2011","journal-title":"Am J Nephrol"},{"key":"2026070811345950200_bib73","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/01.HYP.0000176588.51027.35","article-title":"c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats","volume":"46","author":"Callera","year":"2005","journal-title":"Hypertension"},{"key":"2026070811345950200_bib74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/bbrc.1995.2106","article-title":"Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha","volume":"213","author":"Christ","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"2026070811345950200_bib75","first-page":"805","article-title":"Rapid aldosterone effects on tyrosine phosphorylation in vascular smooth muscle cells","volume":"45","author":"Manegold","year":"1999","journal-title":"Cell Mol Biol"},{"key":"2026070811345950200_bib76","first-page":"3517","article-title":"Rapid cardiovascular action of aldosterone in man","volume":"83","author":"Wehling","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070811345950200_bib77","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0021-9150(02)00363-5","article-title":"Aldosterone induces contraction of the resistance arteries in man","volume":"166","author":"Romagni","year":"2003","journal-title":"Atherosclerosis"},{"key":"2026070811345950200_bib78","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/01.HYP.0000083298.23119.16","article-title":"Rapid nongenomic effects of aldosterone on human forearm vasculature","volume":"42","author":"Schmidt","year":"2003","journal-title":"Hypertension"},{"key":"2026070811345950200_bib79","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3317\/jraas.2002.013","article-title":"Lack of rapid aldosterone effects on forearm resistance vasculature in health","volume":"3","author":"Gunaruwan","year":"2002","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2026070811345950200_bib80","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1210\/me.2004-0469","article-title":"Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions","volume":"19","author":"Grossmann","year":"2005","journal-title":"Mol Endocrinol"},{"key":"2026070811345950200_bib81","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1210\/ME.2014-1410","article-title":"Role of nongenomic signaling pathways activated by aldosterone during cardiac reperfusion injury","volume":"29","author":"Ashton","year":"2015","journal-title":"Mol Endocrinol"},{"key":"2026070811345950200_bib82","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.110.161653","article-title":"GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone","volume":"57","author":"Gros","year":"2011","journal-title":"Hypertension"},{"key":"2026070811345950200_bib83","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/en.2004-1102","article-title":"Homeostatic responses in the adrenal cortex to the absence of aldosterone in mice","volume":"146","author":"Lee","year":"2005","journal-title":"Endocrinology"},{"key":"2026070811345950200_bib84","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1210\/en.2008-1296","article-title":"Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta","volume":"150","author":"Luther","year":"2009","journal-title":"Endocrinology"},{"key":"2026070811345950200_bib85","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ki.2012.170","article-title":"Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury","volume":"82","author":"Luther","year":"2012","journal-title":"Kidney Int"},{"key":"2026070811345950200_bib86","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99015","article-title":"Aldosterone deficiency in mice burdens respiration and accentuates diet-induced hyperinsulinemia and obesity","volume":"3","author":"Liao","year":"2018","journal-title":"JCI Insight"},{"key":"2026070811345950200_bib87","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/biology13121084","article-title":"The effects of aldosterone on hypertension-associated kidney injury in a Tg-hAS mouse model","volume":"13","author":"Gu","year":"2024","journal-title":"Biology"},{"key":"2026070811345950200_bib88","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation"},{"key":"2026070811345950200_bib89","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ki.2009.9","article-title":"Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt","volume":"75","author":"Lea","year":"2009","journal-title":"Kidney Int"},{"key":"2026070811345950200_bib90","doi-asserted-by":"crossref","first-page":"F1402","DOI":"10.1152\/ajprenal.00691.2010","article-title":"Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats","volume":"300","author":"Kawarazaki","year":"2011","journal-title":"Am J Physiol Ren Physiol"},{"key":"2026070811345950200_bib91","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/en.2007-0584","article-title":"Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone","volume":"149","author":"Minnaard-Huiban","year":"2008","journal-title":"Endocrinology"},{"key":"2026070811345950200_bib92","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","article-title":"Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone","volume":"29","author":"Mulder","year":"2008","journal-title":"Eur Heart J"},{"key":"2026070811345950200_bib93","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/cvr\/cvn222","article-title":"Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction","volume":"81","author":"Huang","year":"2009","journal-title":"Cardiovasc Res"},{"key":"2026070811345950200_bib94","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1113\/expphysiol.2008.042085","article-title":"Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats","volume":"93","author":"Siragy","year":"2008","journal-title":"Exp Physiol"},{"key":"2026070811345950200_bib95","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1210\/en.2016-1358","article-title":"Aldosterone synthase inhibition improves glucose tolerance in zucker diabetic fatty (ZDF) rats","volume":"157","author":"Hofmann","year":"2016","journal-title":"Endocrinology"},{"key":"2026070811345950200_bib96","doi-asserted-by":"crossref","first-page":"12450","DOI":"10.1096\/fj.202000164R","article-title":"The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway","volume":"34","author":"Marzolla","year":"2020","journal-title":"FASEB J"},{"key":"2026070811345950200_bib97","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cvr\/cvp191","article-title":"Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice","volume":"84","author":"Hirata","year":"2009","journal-title":"Cardiovasc Res"},{"key":"2026070811345950200_bib98","doi-asserted-by":"crossref","first-page":"E110","DOI":"10.1152\/ajpendo.00258.2007","article-title":"Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG (mRen2) 27 rat","volume":"295","author":"Lastra","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026070811345950200_bib99","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1097\/HJH.0b013e32833c2197","article-title":"FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice","volume":"28","author":"Gamliel-Lazarovich","year":"2010","journal-title":"J Hypertens"},{"key":"2026070811345950200_bib100","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/s-0043-101821","article-title":"The aldosterone synthase inhibitor FAD286 is suitable for lowering aldosterone levels in ZDF rats but not in db\/db mice","volume":"49","author":"Hofmann","year":"2017","journal-title":"Horm Metab Res"},{"key":"2026070811345950200_bib101","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.111.188136","article-title":"Neovascularization is attenuated with aldosterone synthase inhibition in rats with retinopathy","volume":"59","author":"Deliyanti","year":"2012","journal-title":"Hypertension"},{"key":"2026070811345950200_bib102","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqac201","article-title":"Aldosterone as a possible contributor to eye diseases","volume":"164","author":"Higashide","year":"2022","journal-title":"Endocrinology"},{"key":"2026070811345950200_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107902","article-title":"Angiotensin II and aldosterone activate retinal microglia","volume":"191","author":"Rana","year":"2020","journal-title":"Exp Eye Res"},{"key":"2026070811345950200_bib104","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1055\/s-0043-113829","article-title":"Impact of aldosterone synthase inhibitor FAD286 on steroid hormone profile in human adrenocortical cells","volume":"49","author":"Brunssen","year":"2017","journal-title":"Horm Metab Res"},{"key":"2026070811345950200_bib105","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"2026070811345950200_bib106","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1210\/jc.2019-00217","article-title":"Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of cushing syndrome: an in vitro study","volume":"104","author":"Creemers","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070811345950200_bib107","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1507\/endocrj.EJ19-0617","article-title":"A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11\u03b2-hydroxylase inhibitor, in Japanese patients with endogenous Cushing\u2019s syndrome other than Cushing\u2019s disease","volume":"67","author":"Tanaka","year":"2020","journal-title":"Endocr J"},{"key":"2026070811345950200_bib108","doi-asserted-by":"crossref","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070811345950200_bib109","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-22-0317","article-title":"Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026070811345950200_bib110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","article-title":"Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers","volume":"46","author":"Freeman","year":"2023","journal-title":"Hypertens Res"},{"key":"2026070811345950200_bib111","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70000","article-title":"First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor","volume":"17","author":"Shimizu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026070811345950200_bib112","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070811345950200_bib113","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1042\/CS20220212","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with type 2 diabetes and chronic kidney disease","volume":"136","author":"Barrera-Chimal","year":"2022","journal-title":"Clin Sci"},{"key":"2026070811345950200_bib114","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070811345950200_bib115","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2026070811345950200_bib116","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"2026070811345950200_bib117","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","article-title":"Finerenone added to RAS\/SGLT2 blockade for CKD in Alport syndrome. Results of a randomized controlled trial with Col4a3\u2212\/\u2212 mice","volume":"34","author":"Zhu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2026070811345950200_bib118","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026070811345950200_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-74934-z","article-title":"Benefit of combination therapy with dapagliflozin and eplerenone on cardiac function and fibrosis in rats with non-diabetic chronic kidney disease","volume":"14","author":"Soulie","year":"2024","journal-title":"Sci Rep"},{"key":"2026070811345950200_bib120","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2025","journal-title":"Circulation"},{"key":"2026070811345950200_bib121","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized cross-over clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026070811345950200_bib122","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"2026070811345950200_bib123","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"2026070811345950200_bib124","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","volume":"40","author":"Judge","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026070811345950200_bib125","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.122.19159","article-title":"Mineralocorticoid receptor antagonists cause natriuresis in the absence of aldosterone","volume":"79","author":"Maeoka","year":"2022","journal-title":"Hypertension"}],"container-title":["Journal of Molecular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jme.bioscientifica.com\/view\/journals\/jme\/75\/3\/JME-25-0047.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jme.bioscientifica.com\/downloadpdf\/journals\/jme\/75\/3\/JME-25-0047.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/jme\/article-pdf\/doi\/10.1530\/JME-25-0047\/247121\/jme-25-0047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/jme\/article-pdf\/doi\/10.1530\/JME-25-0047\/247121\/jme-25-0047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:35:21Z","timestamp":1783524921000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/jme\/article\/75\/3\/e250047\/14650\/Aldosterone-synthase-inhibition-a-novel-bullet-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1530\/jme-25-0047","relation":{},"ISSN":["1479-6813","0952-5041"],"issn-type":[{"value":"1479-6813","type":"electronic"},{"value":"0952-5041","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"article-number":"e250047"}}